Skip to main content

Table 2 Clinicopathological characteristics of patients grouped by the optimal cut-off value of eLNs before and after PSM analysis

From: A novel pN3 gastric cancer staging system with superior prognostic utility based upon the examination of over 31 lymph nodes: a propensity score-matching analysis

Characteristic

Before PSM analysis

After PSM analysis

Examined ≤ 31 LNs (n = 2032)

 

Examined > 31 LNs (n = 862)

 

P value

Examined ≤ 31 LNs (n = 857)

 

Examined > 31 LNs (n = 857)

 

P value

n

%

n

%

 

n

%

n

%

 

Age

    

0.097

    

0.920

 ≤ 60

689

33.9

320

37.1

 

317

37.0

315

36.8

 

 > 60

1343

66.1

542

62.9

 

540

63.0

542

63.2

 

Race

    

0.213

    

0.143

White

1180

58.1

479

55.6

 

507

59.2

477

55.7

 

Black/Others*

852

41.9

383

44.4

 

350

40.8

380

44.3

 

Sex

    

0.758

    

0.128

Male

1170

57.6

491

57.0

 

519

60.6

488

56.9

 

Female

862

42.4

371

43.0

 

338

39.4

369

43.1

 

Primary site

    

0.164

    

0.806

Upper

80

3.9

35

4.1

 

35

4.1

35

4.1

 

Middle

235

11.6

123

14.3

 

112

13.1

121

14.1

 

Lower

786

38.7

295

34.2

 

320

37.3

294

34.3

 

Curvature

461

22.7

207

24.0

 

188

21.9

206

24.0

 

Overlapping lesion

274

13.5

124

14.4

 

122

14.2

123

14.4

 

Stomach, NOS

196

9.6

78

9.1

 

80

9.3

78

9.1

 

Grade

    

0.053

    

0.154

Well differentiated

14

0.7

4

0.5

 

7

0.8

4

0.5

 

Moderately differentiated

295

41.5

111

12.9

 

119

13.9

108

12.6

 

Poorly differentiated

1656

81.5

732

84.9

 

704

82.1

730

85.2

 

Undifferentiated

67

3.3

15

1.7

 

27

3.2

15

1.8

 

Size

    

0.006

    

0.074

 ≤ 6 cm

1095

53.9

416

48.3

 

451

52.6

414

48.3

 

 > 6 cm

937

46.1

446

51.7

 

406

47.4

443

51.7

 

pT stage

    

0.394

    

0.441

pT1a

7

0.3

3

0.4

 

4

0.5

3

0.4

 

pT1b

39

1.9

20

2.3

 

19

2.2

20

2.3

 

pT2

109

5.4

43

5.0

 

45

5.3

41

4.8

 

pT3

866

42.6

354

41.1

 

373

43.5

352

41.1

 

pT4a

752

37.0

350

40.6

 

308

35.9

349

40.7

 

pT4b

259

12.7

92

10.7

 

108

12.6

92

10.7

 

pN stage

    

 < 0.001

    

0.923

pN3a

1380

67.9

383

44.4

 

381

44.5

383

44.7

 

pN3b

652

32.1

479

55.6

 

476

55.5

474

55.3

 

TNM stage

    

 < 0.001

    

0.951

IIB

39

1.9

16

1.9

 

19

2.2

16

1.9

 

IIIA

90

4.4

28

3.3

 

28

3.3

28

3.3

 

IIIB

1118

55.0

329

38.2

 

320

37.3

327

38.2

 

IIIC

785

38.6

489

56.7

 

490

57.2

486

56.7

 

Adjuvant therapy

    

 < 0.001

    

0.064

Observation

710

34.9

244

28.3

 

265

30.9

244

28.5

 

ART

56

2.8

27

3.1

 

23

2.7

27

3.2

 

ACT

426

21.0

238

27.6

 

192

22.4

238

27.8

 

ACRT

840

41.3

353

41.0

 

377

44.0

348

40.6

 
  1. Bold values indicate the significant difference with P < 0.05
  2. n, number of patients; LNs, lymph nodes; PSM, propensity score matching; NOS, not otherwise specified; ART, adjuvant radiotherapy; ACT, adjuvant chemotherapy; ACRT, adjuvant chemoradiotherapy
  3. *Referring to American Indian/AK Native, Asian/Pacific Islander